First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome

Press/Media

Period	5 May 2020 → 6 May 2020

Media coverage

22

Media coverage

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	Morningstar.com
Country/Territory	United States
Date	6/05/20
URL	https://www.morningstar.com/news/globe-newswire/7915504/first-patients-dosed-in-phase-23-randomized-controlled-trial-of-mesoblasts-remestemcel-l-for-covid-19-acute-respiratory-distress-syndrome
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast's Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	TMC Net
Country/Territory	United States
Date	6/05/20
URL	www.tmcnet.com/usubmit/-first-patients-dosed-phase-23-randomized-controlled-trial-/2020/05/06/9145294.htm
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast's Remestemcel-l for COVID-19 …
Media name/outlet	TMC Net
Country/Territory	United States
Date	6/05/20
URL	www.tmcnet.com/usubmit/2020/05/06/9145294.htm
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast's Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	MarketScreener.com
Country/Territory	United States
Date	6/05/20
URL	https://www.marketscreener.com/MESOBLAST-LIMITED-6499027/news/First-Patients-Dosed-in-Phase-2-3-Randomized-Controlled-Trial-of-Mesoblast-s-Remestemcel-l-for-COVI-30547911/
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	WVB
Country/Territory	United States
Date	6/05/20
URL	wvb.com/news/industry/view/id/8032256
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	Market Newsdesk
Country/Territory	United States
Date	6/05/20
URL	www.marketnewsdesk.com/?p=262820
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast ’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	Stockwatch
Country/Territory	Canada
Date	6/05/20
URL	www.stockwatch.com/News/Item?bid=U-z7915504-U%3aMESO-20200506&symbol=MESO&region=U
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	Markets Business Insider
Country/Territory	United States
Date	6/05/20
URL	www.quotenet.com/news/stocks/first-patients-dosed-in-phase-2-3-randomized-controlled-trial-of-mesoblast-s-remestemcel-l-for-covid-19-acute-respiratory-distress-syndrome-1029169646
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	Crwe World
Country/Territory	United States
Date	6/05/20
URL	crweworld.com/article/news-provided-by-globenewswire/1522117/first-patients-dosed-in-phase-23-randomized-controlled-trial-of-mesoblasts-remestemcel-l-for-covid-19-acute-respiratory-distress-syndrome
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast's Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	Customer Zone 360.com
Country/Territory	United States
Date	6/05/20
URL	www.customerzone360.com/news/2020/05/06/9145294.htm
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	Jotup
Country/Territory	United States
Date	6/05/20
URL	https://jotup.co/node/765470
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	Biotechgate
Country/Territory	Switzerland
Date	6/05/20
URL	www.biotechgate.com/gate/v3/news_details.php?news_id=200953&page_id=?next=1
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast's Remestemcel l for COVID 19 Acute Respiratory Distress Syndrome
Media name/outlet	Market News Publishing
Country/Territory	United States
Date	6/05/20
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	BioSpace
Country/Territory	United States
Date	6/05/20
URL	https://www.biospace.com/article/releases/first-patients-dosed-in-phase-2-3-randomized-controlled-trial-of-mesoblast-s-remestemcel-l-for-covid-19-acute-respiratory-distress-syndrome/?s=95
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	FirstWord Pharma
Country/Territory	United States
Date	6/05/20
URL	www.firstwordpharma.com/node/1721807
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	GlobeNewswire
Country/Territory	United States
Date	6/05/20
URL	https://www.globenewswire.com/news-release/2020/05/06/2028234/0/en/First-Patients-Dosed-in-Phase-2-3-Randomized-Controlled-Trial-of-Mesoblast-s-Remestemcel-l-for-COVID-19-Acute-Respiratory-Distress-Syndrome.html
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory ...
Media name/outlet	EIN Presswire
Country/Territory	United States
Date	6/05/20
URL	https://www.einpresswire.com/article/516330279/first-patients-dosed-in-phase-2-3-randomized-controlled-trial-of-mesoblast-s-remestemcel-l-for-covid-19-acute-respiratory-distress-syndrome
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast's Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	PrimeNewswire (Top News)
Country/Territory	United States
Date	6/05/20
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	EIN News
Country/Territory	United States
Date	6/05/20
URL	https://www.einnews.com/pr_news/516330279/first-patients-dosed-in-phase-2-3-randomized-controlled-trial-of-mesoblast-s-remestemcel-l-for-covid-19-acute-respiratory-distress-syndrome
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast's Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	MarketScreener.com
Country/Territory	United States
Date	6/05/20
URL	https://www.marketscreener.com/MESOBLAST-LIMITED-6499027/news/First-Patients-Dosed-in-Phase-2-3-Randomized-Controlled-Trial-of-Mesoblast-s-Remestemcel-l-for-COVI-30547911/?utm_medium=RSS&utm_content=20200506
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	GlobeNewswire
Country/Territory	United States
Date	6/05/20
URL	www.globenewswire.com/news-release/2020/05/06/2028234/0/en/First-Patients-Dosed-in-Phase-2-3-Randomized-Controlled-Trial-of-Mesoblast-s-Remestemcel-l-for-COVID-19-Acute-Respiratory-Distress-Syndrome.html
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns

Title	First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome
Media name/outlet	Global Banking & Finance Review
Country/Territory	United Kingdom
Date	5/05/20
URL	https://www.globalbankingandfinance.com/category/news/first-patients-dosed-in-phase-2-3-randomized-controlled-trial-of-mesoblasts-remestemcel-l-for-covid-19-acute-respiratory-distress-syndrome/
Persons	Alan Moskowitz, Emilia Bagiella, Annetine Gelijns